82/100 · Critical
Manufactured by Pharmacia & Upjohn Company LLC
Methyprednisolone Adverse Events: High Seriousness and Diverse Reactions
337,823 FDA adverse event reports analyzed
Last updated: 2026-05-12
METHYLPREDNISOLONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Pharmacia & Upjohn Company LLC. Based on analysis of 337,823 FDA adverse event reports, METHYLPREDNISOLONE has a safety score of 82 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for METHYLPREDNISOLONE include OFF LABEL USE, DRUG INEFFECTIVE, FATIGUE, PAIN, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for METHYLPREDNISOLONE.
Methylprednisolone has a safety concern score of 82 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 337,823 adverse event reports for this medication, which is primarily manufactured by Pharmacia & Upjohn Company Llc.
The most commonly reported adverse events include Off Label Use, Drug Ineffective, Fatigue. Of classified reports, 90.0% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. The majority of adverse events are serious, with a high percentage of reports involving respiratory and gastrointestinal issues.
A wide range of reactions are reported, indicating diverse safety concerns. The drug is frequently reported to be ineffective, especially for unapproved indications.
Patients taking Methylprednisolone should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Methyprednisolone can cause serious adverse events such as pneumonia, sepsis, and respiratory failure. It is important to monitor patients for these conditions, especially those with pre-existing respiratory issues. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Methylprednisolone received a safety concern score of 82/100 (high concern). This is based on a 90.0% serious event ratio across 131,733 classified reports. The score accounts for 337,823 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 65,010, Male: 48,449, Unknown: 401. The most frequently reported age groups are age 65 (2,178 reports), age 60 (2,148 reports), age 63 (2,031 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 131,733 classified reports for METHYLPREDNISOLONE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Methyprednisolone can cause serious adverse events such as pneumonia, sepsis, and respiratory failure. It is important to monitor patients for these conditions, especially those with pre-existing respiratory issues.
If you are taking Methylprednisolone, here are important things to know. The most commonly reported side effects include off label use, drug ineffective, fatigue, pain, nausea. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should report any serious adverse events to their healthcare provider immediately. Follow the prescribed dosage and indications strictly to avoid drug ineffectiveness and other adverse reactions. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor the safety of methyprednisolone and has not issued any specific warnings or changes to the drug label based on these reports.
The FDA has received approximately 337,823 adverse event reports associated with Methylprednisolone. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Methylprednisolone include Off Label Use, Drug Ineffective, Fatigue, Pain, Nausea. By volume, the top reported reactions are: Off Label Use (20,939 reports), Drug Ineffective (15,500 reports), Fatigue (7,794 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Methylprednisolone.
Out of 131,733 classified reports, 118,540 (90.0%) were classified as serious and 13,193 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Methylprednisolone break down by patient sex as follows: Female: 65,010, Male: 48,449, Unknown: 401. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Methylprednisolone adverse events are: age 65: 2,178 reports, age 60: 2,148 reports, age 63: 2,031 reports, age 58: 2,026 reports, age 61: 2,021 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Methylprednisolone adverse event reports is Pharmacia & Upjohn Company Llc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Methylprednisolone include: Headache, Pyrexia, Pneumonia, Arthralgia, Dyspnoea. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Methylprednisolone to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Methylprednisolone has a safety concern score of 82 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. The majority of adverse events are serious, with a high percentage of reports involving respiratory and gastrointestinal issues.
Key safety signals identified in Methylprednisolone's adverse event data include: High number of serious adverse events (118,540 out of 131,733 total, 90%). Common reactions include pneumonia, dyspnoea, and infection. Significant reports of drug ineffectiveness and product use issues. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Methyprednisolone can cause serious adverse events such as pneumonia, sepsis, and respiratory failure. It is important to monitor patients for these conditions, especially those with pre-existing respiratory issues. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Methylprednisolone.
Patients should report any serious adverse events to their healthcare provider immediately. Follow the prescribed dosage and indications strictly to avoid drug ineffectiveness and other adverse reactions.
Methylprednisolone has 337,823 adverse event reports on file with the FDA. A wide range of reactions are reported, indicating diverse safety concerns. The volume of reports for Methylprednisolone reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor the safety of methyprednisolone and has not issued any specific warnings or changes to the drug label based on these reports. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Pharmacia & Upjohn Company LLC and compare their safety profiles:
The following drugs share commonly reported adverse reactions with METHYLPREDNISOLONE:
Drugs related to METHYLPREDNISOLONE based on therapeutic use, drug class, or shared indications: